Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Sees Large Decline in Short Interest

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX - Get Free Report) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 36,100 shares, a drop of 23.2% from the February 13th total of 47,000 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 830,300 shares, the short-interest ratio is currently 0.0 days.

Biodexa Pharmaceuticals Stock Performance

Shares of NASDAQ BDRX traded up $0.22 during mid-day trading on Wednesday, reaching $2.24. The company had a trading volume of 27,964,020 shares, compared to its average volume of 472,120. Biodexa Pharmaceuticals has a one year low of $1.84 and a one year high of $74.00. The company has a 50-day moving average price of $3.81.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.